MHRA updates Guidance on Sourcing Medicines for the UK Market
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The UK Medicines & Healthcare Products Regulatory Agency (MHRA) has updated its guidance on sourcing medicines for the UK market.
The document, which was first published on 31 December 2020, provides information on sourcing medicines that can be supplied by holders of wholesale distributor authorisations (WDAs) based in the UK.
The guidance covers the following aspects:
- Importing authorised medicines into the UK from a source which is on the approved country for import list
- Importing human medicines from a country on the list – for use as a special medicinal product
- Procuring human medicines from a country on the list for export purposes
- Importing medicines from a country on the list for supply to the United Kingdom parallel import market
The latest updates, published on 30 December 2024, reflect the new UK-wide licensing arrangements for human medicines that came into effect from 01 January 2025 as part of the Windsor Framework.
The complete guidance is available on the MHRA website.
Related GMP News
30.09.2026European GDP Association Developments May through August 2026
30.09.2026Warehouse Temperature Excursions: What Does the FDA Expect?
30.09.2026Version 4.0 of the Swissmedic Document on Notifications of Changes Published
30.09.2026USA: Court Stops Warehouse Activities Following Persistent Insanitary Warehouse Conditions
30.09.2026GDP Non-Compliance Report: CAPA Measures must not only be Promised but also Implemented
10.09.2026Reminder: Submit your Presentation Proposal for the GDP Forum 2027 by 30 September